Evommune (EVMN) EPS (Basic) (2024 - 2026)

Evommune's (EVMN) quarterly EPS (Basic) came in at -$3.38 in Q1 2026, up 64.56% year-on-year from -$2.05 in Q1 2025, and up 25.71% on a QoQ basis from -$4.54 in Q4 2025.

Evommune (EVMN) EPS (Basic) (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of EPS (Basic) data on file, last reported at -$3.38 in Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 64.56% year-over-year to -$3.38 in Q1 2026; TTM through Mar 2026 was -$5.01, a N/A change from a year earlier, with the FY2025 full-year figure at -$21.55, up 51.89% from the prior year.
  • EPS (Basic) for Q1 2026 stood at -$3.38, up from -$4.54 in the prior quarter.
  • Over the last five years, EPS (Basic) for EVMN reached as high as -$3.38 in Q1 2026 and fell as low as -$13.37 in Q4 2024.
  • Historically, EPS (Basic) has averaged -$8.23 across 3 years, with a median of -$8.8 in 2025.
  • On a YoY basis, EPS (Basic) climbed as much as 66.02% in 2025 and fell as far as 22.85% in 2025.
  • Year by year, EPS (Basic) stood at -$13.37 in 2024, then soared by 66.02% to -$4.54 in 2025, then increased by 25.71% to -$3.38 in 2026.
  • Per Business Quant data, the three most recent EPS (Basic) figures were -$3.38 in Q1 2026, -$4.54 in Q4 2025, and -$8.07 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Basic) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 0.00
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 0.00
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 0.16
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 4.06
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 6.99
7 Belite Bio 61.40 Bn 61.40 Bn - 0.00
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 5.90
9 Revolution Medicines 37.37 Bn 37.37 Bn - -2.29
10 Evommune 380.30 Mn 168.84 Mn - -3.38

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.38
Dec 31, 2025 -4.54
Sep 30, 2025 -8.07
Mar 31, 2025 -9.52
Dec 31, 2024 -13.37
Sep 30, 2024 -10.47